Viking Current Ratio from 2010 to 2025

VKTX Stock  USD 32.65  0.09  0.28%   
Viking Therapeutics Current Ratio yearly trend continues to be fairly stable with very little volatility. Current Ratio will likely drop to 14.10 in 2025. Current Ratio is a liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities. View All Fundamentals
 
Current Ratio  
First Reported
2010-12-31
Previous Quarter
17.27
Current Value
14.1
Quarterly Volatility
18.05269807
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Viking Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Viking Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 319 K, Interest Expense of 75.2 K or Selling General Administrative of 44.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 4.76. Viking financial statements analysis is a perfect complement when working with Viking Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Viking Therapeutics Correlation against competitors.
For more information on how to buy Viking Stock please use our How to Invest in Viking Therapeutics guide.

Latest Viking Therapeutics' Current Ratio Growth Pattern

Below is the plot of the Current Ratio of Viking Therapeutics over the last few years. It is a liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities. Viking Therapeutics' Current Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Viking Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 11.74 X10 Years Trend
Slightly volatile
   Current Ratio   
       Timeline  

Viking Current Ratio Regression Statistics

Arithmetic Mean14.35
Geometric Mean5.20
Coefficient Of Variation125.83
Mean Deviation12.96
Median7.69
Standard Deviation18.05
Sample Variance325.90
Range66.3685
R-Value0.41
Mean Square Error289.53
R-Squared0.17
Significance0.11
Slope1.57
Total Sum of Squares4,888

Viking Current Ratio History

2025 14.1
2024 17.27
2023 19.19
2022 7.61
2021 23.98
2020 21.12
2019 41.83

About Viking Therapeutics Financial Statements

Viking Therapeutics investors use historical fundamental indicators, such as Viking Therapeutics' Current Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Viking Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Ratio 17.27  14.10 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Viking Stock Analysis

When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.